Sortera Bio is a technology company.
Sortera Bio has raised $10.0M across 1 funding round.
Sortera Bio has raised $10.0M in total across 1 funding round.
Sortera Bio has raised $10.0M in total across 1 funding round.
Sortera Bio's investors include Cambridge Innovation Capital, LGT Lightstone, TotalEnergies Ventures.
Sortera Bio is a biotech startup developing AI-powered platforms for biologics drug discovery. It builds Deep Screening, a breakthrough technology that generates massive sequence-function datasets from single experiments to train machine learning models, enabling faster and more precise identification of novel biologics like antibodies, even for challenging targets such as membrane proteins.[5][6] The company serves pharmaceutical and biotech firms tackling tough drug discovery challenges, solving the critical scarcity of high-quality, unbiased real-world data needed to power AI models for biologics design.[6] Co-founded by protein engineering experts, Sortera Bio raised £7.5 million in pre-seed funding, signaling strong early momentum in the AI-biotech intersection.[5][6]
Sortera Bio was co-founded by Dr. Ben Porebski and Dr. Philipp Holliger, both renowned experts in protein engineering and synthetic biology.[5] The idea emerged from the recognized gap in high-quality data for training AI models in biologics discovery, leading to the creation of their Deep Screening platform, which collects hundreds of millions of sequence-function pairs in one experiment to fuel advanced machine learning.[6] Early traction includes a £7.5 million pre-seed raise, positioning the company to partner with world-leading pharma firms from the outset.[5][6]
Sortera Bio rides the AI-biotech convergence trend, where machine learning accelerates drug discovery amid rising demand for biologics to treat complex diseases.[6] Timing is ideal as AI models hunger for proprietary, high-fidelity data—Sortera's platform fills this void, reducing reliance on synthetic or biased datasets that hinder model performance.[5][6] Market forces like surging biologics R&D (projected to dominate new approvals) and computational biology advances favor its growth, while it influences the ecosystem by enabling pharma partners to de-risk tough targets and shorten timelines from years to months.[6]
Sortera Bio is poised for rapid scaling through strategic pharma partnerships and dataset expansion, potentially licensing Deep Screening widely as AI models mature.[5][6] Trends like multimodal AI integration and membrane protein breakthroughs will amplify its edge, evolving its role from data generator to core enabler in next-gen drug design. As the "game-changing approach" to biologics, it could redefine discovery standards, delivering the high-quality data that powers tomorrow's therapies.[6]
Sortera Bio has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Seed in June 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2025 | $10.0M Seed | Cambridge Innovation Capital, LGT Lightstone, TotalEnergies Ventures |